Trial · NCT03150589
Adverse events204
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 204
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Neovascular age-related macular degeneration | Eye disorders | SB11 (Proposed Ranibizumab Biosimilar) | 26 | 350 | 26 |
| other | Neovascular age-related macular degeneration | Eye disorders | Lucentis (Ranibizumab) | 24 | 354 | 24 |
| other | Visual acuity reduced | Eye disorders | SB11 (Proposed Ranibizumab Biosimilar) | 21 | 350 | 27 |
| other | Visual acuity reduced | Eye disorders | Lucentis (Ranibizumab) | 23 | 354 | 31 |
| other | Conjunctival haemorrhage | Eye disorders | SB11 (Proposed Ranibizumab Biosimilar) | 19 | 350 | 23 |
| other | Conjunctival haemorrhage | Eye disorders | Lucentis (Ranibizumab) | 19 | 354 | 21 |
| other | Nasopharyngitis | Infections and infestations | SB11 (Proposed Ranibizumab Biosimilar) | 39 | 350 | 44 |
| other | Nasopharyngitis | Infections and infestations | Lucentis (Ranibizumab) | 36 | 354 | 41 |
| other | Intraocular pressure increased | Investigations | SB11 (Proposed Ranibizumab Biosimilar) | 24 | 350 | 47 |
| other | Intraocular pressure increased | Investigations | Lucentis (Ranibizumab) | 29 | 354 | 77 |
| other | Hypertension | Vascular disorders | SB11 (Proposed Ranibizumab Biosimilar) | 17 | 350 | 18 |
| other | Hypertension | Vascular disorders | Lucentis (Ranibizumab) | 28 | 354 | 39 |
| serious | Anaemia | Blood and lymphatic system disorders | SB11 (Proposed Ranibizumab Biosimilar) | 1 | 350 | 1 |
| serious | Anaemia | Blood and lymphatic system disorders | Lucentis (Ranibizumab) | 1 | 354 | 1 |
| serious | Atrial fibrillation | Cardiac disorders | SB11 (Proposed Ranibizumab Biosimilar) | 4 | 350 | 4 |
| serious | Atrial fibrillation | Cardiac disorders | Lucentis (Ranibizumab) | 3 | 354 | 3 |
| serious | Cardiac failure congestive | Cardiac disorders | SB11 (Proposed Ranibizumab Biosimilar) | 2 | 350 | 2 |
| serious | Cardiac failure congestive | Cardiac disorders | Lucentis (Ranibizumab) | 2 | 354 | 2 |
| serious | Angina pectoris | Cardiac disorders | SB11 (Proposed Ranibizumab Biosimilar) | 1 | 350 | 1 |
| serious | Angina pectoris | Cardiac disorders | Lucentis (Ranibizumab) | 1 | 354 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03150589/events